PEPG — PepGen Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1835597 ·
Last close
$3.88
Market Cap
$365.73M
52W High
$7.80
52W Low
$1.31
ADV30
5,789,839
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -20,383,000 | -19,391,000 | 127,777,000 | 21,957,000 | 24,711,000 |
| Jun 2026 | 0 | — | -18,939,000 | -17,812,000 | 141,397,000 | 22,764,000 | 21,864,000 |
| Mar 2026 | 0 | — | -18,942,000 | -17,763,000 | 156,295,000 | 42,150,000 | 22,315,000 |
| Dec 2025 | 0 | — | -19,705,000 | -18,340,000 | 173,907,000 | 60,514,000 | 26,463,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-63,252,000
Investing CF
$-58,761,000
Financing CF
$1,196,000
CapEx
$-265,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.07
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-416,084,000
Inventory
—
Receivables
—
ST Investments
$82,848,000
EBIT TTM
$-77,969,000
Pretax Income TTM
$-73,213,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -93,612,000 | -89,655,000 | 173,907,000 | 26,463,000 | 147,444,000 | -81,635,000 |
| Dec 2024 | 0 | -97,739,000 | -89,981,000 | 150,883,000 | 32,263,000 | 118,620,000 | -82,372,000 |
| Dec 2023 | 0 | -84,766,000 | -78,626,000 | 143,052,000 | 34,631,000 | 108,421,000 | -68,997,000 |
| Dec 2022 | 0 | -68,301,000 | -69,104,000 | 217,440,000 | 37,809,000 | 179,631,000 | -59,265,000 |
TTM Snapshot
Revenues TTM
$4,396,000
NetIncome TTM
$-71,941,000
OpCashFlow TTM
—
Assets (Latest)
$141,397,000
Forward EPS
$-1.17
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $3.83 · call volume: 64 · put volume: 239
Expected Move to 2027-02-19:
±$2.62
(68.41%) —
implied range
$1.21 –
$6.45
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYDY | CytoDyn Inc. | $366.64M | $0.25 | — |
| SPRY | ARS Pharmaceuticals, Inc. | $366.93M | $3.65 | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $369.13M | $7.14 | — |
| NIKA | NIKA PHARMACEUTICALS, INC | $369.14M | $0.35 | — |
| CRMD | CorMedix Inc. | $371.44M | $4.67 | — |
News headlines (Yahoo Finance, 1h cache)
PepGen (PEPG) Stock Sees Fair Value Lift After Encouraging EDODM1 Analyst Reactions
2026-11-13 01:16 · Yahoo
PepGen Announces Pricing of $125 Million Public Offering
2026-11-12 03:22 · Yahoo
PepGen’s stock skyrockets on record-breaking DM1 trial data
2026-11-11 18:19 · Yahoo
PepGen soars on promising early data for muscular dystrophy drug
2026-11-10 21:48 · Yahoo
PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
2026-11-10 21:23 · Yahoo
PepGen Stock Spikes 132% on Rare-Disease Win. These Rivals Are Feeling The Pressure.
2026-11-10 18:48 · Yahoo
PepGen Stock Doubles in One Session - Here's Why
2026-11-10 18:47 · Yahoo
PepGen Reports Phase 2 Myotonic Dystrophy Trial Results and $104.8 Million Cash Position
2026-11-10 15:56 · Yahoo
PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
2026-11-10 12:05 · Yahoo
PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures
2026-11-10 12:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.